Drug Trial Radar · NCT06370039
Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye Disease
Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
109
Actual
Start
Mar 27, 2024
Primary completion
Jul 3, 2024
Study completion Jul 3, 2024
Sponsor
- Lead sponsor
- Invirsa, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Biomedical Advanced Research and Development Authority
- First posted
- Apr 17, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 2 study to assess the efficacy of topically administered eyedrops of INV-102 during 4-week repeat dosing in subjects with moderate to severe dry eye disease.
Conditions
- Dry Eye Disease
Interventions
INV-102Drug
INV-102 Ophthalmic Solution
VehicleDrug
Vehicle Ophthalmic Solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in corneal fluorescein staining total score on the National Eye Institute (NEI)/Industry scaleTime frame: Baseline to Day 29
Locations
1 site in 1 country. Site status is shown where the registry gives one.
iuvo BioScience
Rush, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.